An Official Website of the United States Government
Company Information:
Name:
PLX PHARMA, INC.
Address:
8285 EL RIO
HOUSTON, TX 77054-
HOUSTON, TX 77054-
Located in HUBZone:
Yes
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
PC-NSAIDs: Gastrointestinal-safe and potent anti-inflammatory drugs
Award Year / Program / Phase:
2007 / SBIR / Phase I
Agency / Branch:
DOD / ARMY
Principal Investigator:
Upendra Marathi, Senior Vice President
Award Amount:
$69,997.00
Abstract:
Contrasting in vitro and in vivo systems will be used to evaluate the anti-inflammatory/analgesic activity and side-effects of a family of phosphatidylcholine (PC) - associated NSAIDs. Previous studies indicate that PC-NSAIDs have equivalent and/or enhanced therapeutic activity while GI… More
PC-NSAIDs: Gastrointestinal-safe and potent anti-inflammatory drugs
Award Year / Program / Phase:
2008 / SBIR / Phase II
Agency / Branch:
DOD / ARMY
Principal Investigator:
Upendra K. Marathi, Senior Vice President
Award Amount:
$729,991.00
Abstract:
We have developed a novel class of phosphatidylcholine (PC)-associated nonsteroidal antiinflammatory drugs (NSAIDs) to treat inflammation and pain with reduced GI side-effects. In Phase I studies using a number of in vitro systems monitoring the activity and threshold of nociceptive fibers under… More
GI-Safer Naproxen Formulation RandD for the Treatment of Osteoarthritis and Relat
Award Year / Program / Phase:
2008 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Award Amount:
$263,605.00
Abstract:
DESCRIPTION (provided by applicant): ABSTRACT: This application is a Phase I/Phase II Fast-Track SBIR application. Osteoarthritis (OA), the clinical syndrome of joint pain and dysfunction caused by joint degeneration, affects more people than any other joi
nt disease. There are no consistently… More
GI-Safer Naproxen Formulation RandD for the Treatment of Osteoarthritis and Related
Award Year / Program / Phase:
2009 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Upendra K. Marathi
Award Amount:
$745,708.00
Abstract:
DESCRIPTION (provided by applicant): ABSTRACT: This application is a Phase I/Phase II Fast-Track SBIR application. Osteoarthritis (OA), the clinical syndrome of joint pain and dysfunction caused by joint degeneration, affects more people than any other joi
nt disease. There are no consistently… More
GI-Safer Formulation of Indomethacin for use in Preterm Neonates
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Upendra K. Marathi
Award Amount:
$157,934.00
Abstract:
DESCRIPTION (provided by applicant): This application is a Phase I SBIR grant application. One of the major causes of morbidity and mortality of low birth weight neonates relates to injury, inflammation, perforation and obstruction of the lower GI tract, w
hich can be manifest in the related… More
GI-Safer Formulation of Indomethacin for use in Preterm Neonates
Award Year / Program / Phase:
2012 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Upendra K. Marathi – 713-842-1249
Award Amount:
$1,118,398.00
Abstract:
DESCRIPTION (provided by applicant): This application is for a SBIR Phase II grant. One of the major causes of morbidity and mortality of low birth weight neonates relates to injury, inflammation, perforation and obstruction of the lower GI tract, which can be manifest in the related diseases… More